文献速递神经肿瘤

世界卫生组织III级(非间变性)脑膜瘤:23例系列经验

World Health Organization Grade III (Nonanaplastic) Meningioma: Experience in a Series of 23 Cases.
PubMed 文献 · World Neurosurg · 2018-01-31

本研究回顾性分析2011年1月至2015年12月本机构23例横纹肌样脑膜瘤(RM)和乳头状脑膜瘤(PM)的临床资料。中位随访38.0个月,平均无进展生存期(PFS)37.6个月,平均总生存期(OS)48.8个月。单因素分析显示Ki-67增殖指数>20%和PM与更差PFS相关;术后放疗(PRT)患者OS更长(中位60.7 vs 35.1个月,P=0.029)。多因素分析显示PRT是PFS和OS的独立因素,RM是PFS和OS的独立因素。作者建议无论切除范围如何均辅以放疗。

要点

  • 23例WHO III级非间变性脑膜瘤(RM和PM)中位随访38.0个月,平均PFS 37.6个月,平均OS 48.8个月。
  • 单因素分析:Ki-67>20%(HR 4.190,95%CI 1.033-17.001,P=0.045)和PM(HR 3.375,95%CI 0.998-11.408,P=0.005)与更差PFS相关。
  • 术后放疗患者中位OS 60.7个月 vs 未放疗35.1个月(P=0.029);多因素分析PRT是PFS(HR 0.147,95%CI 0.033-0.657,P=0.012)和OS(HR 0.130,95%CI 0.025-0.691,P=0.017)的独立因素。

核心结论

  • 作者建议无论切除范围如何均辅以放疗。
  • PM或RM患者复发和死亡风险增加,这些患者的适当治疗应进一步研究,并需要密切随访。

研究设计与样本

  • 回顾性分析2011年1月至2015年12月本机构23例PM和RM的临床资料。

主要发现

  • WHO III级脑膜瘤中位随访38.0个月,平均PFS 37.6个月,1年、3年、5年PFS分别为78.3%、50.8%、43.6%。
  • 平均OS 48.8个月,1年、3年、5年OS分别为95.7%、82.6%、44.0%。
  • 单因素分析显示Ki-67增殖指数>20%(HR 4.190,95%CI 1.033-17.001,P=0.045)和PM(HR 3.375,95%CI 0.998-11.408,P=0.005)与更差PFS相关。
  • 术后放疗患者中位OS 60.7个月 vs 未放疗患者35.1个月(P=0.029)。
  • 多因素分析显示PRT是PFS(HR 0.147,95%CI 0.033-0.657,P=0.012)和OS(HR 0.130,95%CI 0.025-0.691,P=0.017)的独立因素,RM是PFS(HR 7.312,95%CI 1.587-33.688,P=0.011)和OS(HR 6.447,95%CI 1.310-31.740,P=0.022)的独立因素。

临床怎么用

  • 作者建议无论切除范围如何均辅以放疗。
  • 作者认为PM或RM患者复发和死亡风险增加,适当治疗应进一步研究,并需要密切随访。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Rhabdoid meningioma (RM) and papillary meningioma (PM) are rare variants of World Health Organization grade III meningiomas. In this study, we presented a series of 23 cases from our institution to investigate adverse factors of and appropriate treatment for RM and PM. METHODS: Clinical data from 23 cases of PM and RM between January 2011 and December 2015 were retrospectively reviewed. RESULTS: The median follow-up was 38.0 months for World Health Organization grade III meningiomas. The mean progression-free survival (PFS) was 37.6 months, with 1-year, 3-year, and 5-year PFS of 78.3%, 50.8%, and 43.6%, respectively. The mean overall survival (OS) was 48.8 months, with 1-year, 3-year, and 5-year OS of 95.7%, 82.6%, and 44.0%, respectively. Univariate analysis showed that a ki-67 proliferation index >20% (hazard ratio [HR], 4.190; 95% confidence interval [CI], 1.033-17.001; P = 0.045) and PM (HR, 3.375; 95% CI, 0.998-11.408; P = 0.005) were related to worse PFS. Patients administered postoperative radiotherapy (PRT) after surgery had longer OS than did patients who did not receive PRT (median, 60.7 vs. 35.1 months; P = 0.029). Multivariate analysis showed that PRT was an independent factor for PFS (HR, 0.147; 95% CI, 0.033-0.657; P = 0.012) and OS (HR, 0.130; 95% CI, 0.025-0.691; P = 0.017) and that RM was an independent factor for PFS (HR, 7.312; 95% CI, 1.587-33.688; P = 0.011) and OS (HR, 6.447; 95% CI, 1.310-31.740; P = 0.022). CONCLUSIONS: We recommended adjuvant radiation regardless of the extent of resection. Individuals with PM or RM were at increased risk of recurrence and death; appropriate treatment for these patients should be further studied, and close follow-up is needed.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Zhang GJ, Zhang GB, Zhang YS, et al. World Health Organization Grade III (Nonanaplastic) Meningioma: Experience in a Series of 23 Cases. World Neurosurg. 2018. PMID: 29382616. doi:10.1016/j.wneu.2018.01.149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。